エピソード

  • The Biotech Supply Chain Bottleneck

    The Biotech Supply Chain Bottleneck
    2026/09/10
    In this episode of Biotech Business, Lucas and Luna dissect the hidden crisis in life sciences: the critical shortage of single-use bioreactor bags. With global demand outpacing supply, startups are facing lead times of up to six months for essential consumables. We explore how companies like Sartorius and Merck KGaA are expanding capacity, why secondary suppliers are struggling with quality control, and what this means for drug development pipelines in late 2026. The conversation also covers the strategic shift toward vertical integration among mid-tier manufacturers and the financial implications of holding excess inventory during a valuation winter. #BiotechSupplyChain #SingleUseBags #LifeSciencesManufacturing #DrugDevelopment #Sartorius #MerckKGAa #VentureDebt #FDAApprovals #BioPharmaOperations #FexingoBusiness #BusinessPodcast #StartupStrategy #SupplyChainResilience #Bioprocessing #LabEquipment #GlobalHealthcare #OperationalRisk #InvestorRelations Keep every episode free: buymeacoffee.com/fexingo
    続きを読む 一部表示
    11 分
  • How Biotech Startups Are Solving The Protein Degradation Problem

    How Biotech Startups Are Solving The Protein Degradation Problem
    2026/09/09
    We dive into the mechanics and economics of molecular glues and PROTACs, exploring how startups are moving beyond traditional small molecules to selectively tag proteins for destruction. We look at specific clinical progress in targeting previously undruggable disease drivers, the unique manufacturing hurdles of complex biologics, and why this technology is reshaping venture capital valuations in late-stage biotech as of September 2026. #BiotechStartups #DrugDiscovery #ProteinDegraders #MolecularGlues #PROTACs #UndruggableTargets #VentureCapital #FDAApprovals #LifeSciences #BusinessTechnology #FexingoBusiness #BusinessPodcast #LucasAndLuna #PharmaInnovation #ClinicalTrials #DeepTech #HealthcareInvesting #PrecisionMedicine Keep every episode free: buymeacoffee.com/fexingo
    続きを読む 一部表示
    12 分
  • Biotech Startups Navigating The Valuation Winter

    Biotech Startups Navigating The Valuation Winter
    2026/09/08
    In this episode of Biotech Business, Lucas and Luna dissect the structural shift in life sciences financing as September 2026 arrives. With venture capital drying up for early-stage discovery, startups are pivoting from speculative moonshots to asset-light partnerships and strategic mergers. We examine how companies like Gilead Sciences and Merck are acquiring promising pipelines instead of funding them from scratch, and what this means for the future of independent biotech innovation. Listeners will learn why the traditional IPO window is closed for most and how founder-friendly structures are replacing pure equity plays. #BiotechBusiness #FexingoBusiness #LifeSciences #VentureCapital #DrugDiscovery #FDAApprovals #MergersAndAcquisitions #BiotechStartups #PharmaBigFive #ValuationWinter #AssetLight #StrategicPartnerships #ClinicalTrials #GileadSciences #MerckAndCo #HealthcareInvesting #StartupStrategy #BusinessPodcast Keep every episode free: buymeacoffee.com/fexingo
    続きを読む 一部表示
    10 分
  • The Biotech Valuation Winter And The Rise Of Venture Debt

    The Biotech Valuation Winter And The Rise Of Venture Debt
    2026/09/07
    In September 2026, the biotech sector is navigating a sharp divergence between clinical success and capital access. While regulatory approvals for novel therapies continue at a steady clip, traditional venture equity has grown scarce and expensive. This episode examines how startups are pivoting to venture debt and milestone-based financing to extend their runway without diluting early shareholders. We look at the specific mechanics of non-dilutive funding, the rising role of specialized lenders like HGGC and ARK Investment Management, and what this shift means for founders managing cash flow in a high-interest-rate environment. If you are building or running a life sciences company, understanding the trade-offs between debt covenants and equity dilution is no longer optional—it is central to survival. #BiotechFinance #VentureDebt #LifeSciencesStartups #NonDilutiveFunding #ClinicalTrialCosts #FDAApprovals #StartupRunway #BiotechValuation #HGGC #ARKInvestmentManagement #CashFlowManagement #DeepTechInvesting #DrugDiscovery #PharmaPartnerships #BusinessPodcast #FexingoBusiness #Entrepreneurship #CapitalMarkets Keep every episode free: buymeacoffee.com/fexingo
    続きを読む 一部表示
    13 分
  • Why Biotech Patents Are Becoming a Nightmare

    Why Biotech Patents Are Becoming a Nightmare
    2026/09/06
    This episode examines the growing legal and financial crisis in life sciences: the patent cliff. With major blockbuster drugs facing expiration, startups are struggling to secure new intellectual property protection for novel mechanisms like targeted protein degradation and next-generation gene therapies. We explore how the shift from molecule-first to mechanism-first R&D is clashing with outdated patent frameworks, creating uncertainty for investors and developers alike. #BiotechPatents #IntellectualProperty #DrugDiscovery #LifeSciences #FDAApprovals #Startups #BusinessPodcast #FinanceNews #TechInvesting #FexingoBusiness #PatentCliff #PharmaIndustry #InnovationStrategy #VentureCapital #RegulatoryRisk #MarketAnalysis #LucasAndLuna #Episode178 Keep every episode free: buymeacoffee.com/fexingo
    続きを読む 一部表示
    10 分
  • How Biotech Startups Use Organoids for Drug Testing

    How Biotech Startups Use Organoids for Drug Testing
    2026/09/05
    Episode 177 of Biotech Business with Fexingo explores how organoids are replacing traditional animal models in early-stage drug discovery. Lucas and Luna discuss the specific advantages of three-dimensional cell cultures, including patient-specific disease modeling and reduced reliance on rodent trials. They examine real-world applications in neurology and oncology, highlighting why this shift matters for faster FDA approvals and more predictable clinical outcomes. The conversation covers technical challenges like vascularization and scalability, offering listeners a clear understanding of where biotech startups stand today as of September 2026. #BiotechStartups #Organoids #DrugDiscovery #FDAApprovals #LifeSciences #BusinessPodcast #FexingoBusiness #MedicalInnovation #PrecisionMedicine #CellCulture #NeurologyResearch #OncologyTrends #AnimalTestingAlternatives #ClinicalTrials #PharmaTech #HealthcareInvesting #ScienceBusiness #DeepTech Keep every episode free: buymeacoffee.com/fexingo
    続きを読む 一部表示
    13 分
  • How Biotech Startups Use Gene Editing for Rare Diseases

    How Biotech Startups Use Gene Editing for Rare Diseases
    2026/09/04
    We look at the specific mechanics of base editing and prime editing in early-stage biotech, using Vertex Pharmaceuticals as a durable example of how precise genetic fixes are turning previously untreatable conditions into manageable ones. The conversation explores why these tools matter more than broad CRISPR screens for rare disease patients, the regulatory hurdles facing FDA approvals, and the economic reality of pricing one-time cures versus lifetime therapies. We also touch on the supply chain challenges of delivering these edits safely to target tissues. #GeneEditing #BiotechStartups #VertexPharmaceuticals #BaseEditing #PrimeEditing #RareDiseases #FDAApprovals #PrecisionMedicine #GeneticTherapy #ClinicalTrials #CRISPR #HealthcareEconomics #DrugDiscovery #MolecularBiology #PatientOutcomes #RegulatoryPathways #FexingoBusiness #BusinessPodcast Keep every episode free: buymeacoffee.com/fexingo
    続きを読む 一部表示
    8 分
  • Biotech Startups Tackle Drug Development Through AI Simulation

    Biotech Startups Tackle Drug Development Through AI Simulation
    2026/09/03
    We look at how computational biology is reshaping the earliest stages of drug discovery, focusing on the shift from wet-lab screening to in silico modeling. With Lucas and Luna, we examine why this matters for pipeline efficiency, the specific role of generative AI in protein design, and what investors should watch for as these startups move from simulation to clinical reality. This is a deep dive into the technology that could cut years off development timelines. #BiotechInnovation #DrugDiscovery #ComputationalBiology #GenerativeAI #LifeSciences #ProteinDesign #InSilicoTesting #PharmaIndustry #VentureCapital #StartupGrowth #MolecularModeling #DigitalHealth #ScienceTech #FexingoBusiness #BusinessPodcast #InvestorInsights #BiotechTrends #FutureOfMedicine Keep every episode free: buymeacoffee.com/fexingo
    続きを読む 一部表示
    9 分